Thynk Capital — 2020 Investments
1 investments dated 2020 · listed companies and verified rows first · show all
Elevian is a biotechnology company developing rGDF11, a recombinant protein therapy shown in preclinical animal models to promote recovery of motor function after ischemic and hemorrhagic stroke by stimulating new blood vessel formation, neurogenesis, and reducing inflammation.
BiotechHealthtechLongevityMenlo Park, US
Mark Allen(Executive Officer, Director)Casey J McGlynn(Executive Officer)Sebastian Giwa(Executive Officer, Director)Luis Alvarez(Executive Officer)Daniel Marshak(Director)
BoardSuzanne Fletcher(Director)
PartnerJim Plante· solo GP
Co-investorsBold Capital PartnersBOLD CapitalFor Good VenturesLauder PartnersPrime Movers LabWTI
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.